Shota Kinoshita

Shota Kinoshita

Auto-generated profile, based on publicly available information

Shota Kinoshita

Department of Otolaryngology‐Head and Neck Surgery Kyoto Prefectural University of Medicine Kyoto Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in The Laryngoscope
Verified
Journal Article
Closed access
MKMami Kaneko
Mami Kaneko
YSYoichiro Sugiyama
Yoichiro Sugiyama
RMRyoto Munekawa
Ryoto Munekawa
SKShota Kinoshita
Shota Kinoshita
SMShigeyuki Mukudai
Shigeyuki Mukudai
SHShigeru Hirano
Shigeru Hirano

17 October 2022 in The Laryngoscope
Verified
Journal Article
Closed access
HMHiroki Matsushita
Hiroki Matsushita
SMShigeyuki Mukudai
Shigeyuki Mukudai
SOSatomi Ozawa
Satomi Ozawa
SKShota Kinoshita
Shota Kinoshita
KHKeiko Hashimoto
Keiko Hashimoto
SHShigeru Hirano
Shigeru Hirano

1 December 2019 in Auris Nasus Larynx
Verified
Journal Article
Closed access
AAAkihito Arai
Akihito Arai
SOSatomi Ozawa
Satomi Ozawa
SKShota Kinoshita
Shota Kinoshita
KYKanako Yoshimura
Kanako Yoshimura
JMJunichi Mitsuda
Junichi Mitsuda
SHShigeru Hirano
Shigeru Hirano

14 November 2026 in JMIR Preprints
Verified
Preprint
Open access
SMShigeyuki Mukudai
Shigeyuki Mukudai
YSYoichiro Sugiyama
Yoichiro Sugiyama
KHKeiko Hashimoto
Keiko Hashimoto
SFShinya Fuse
Shinya Fuse
SKShota Kinoshita
Shota Kinoshita
SHShigeru Hirano
Shigeru Hirano
BACKGROUND Vocal fold scar and sulcus are refractory disorders characterized by fibrotic changes of the vocal folds that result in persistent dysphonia. Currently, no established pharmacological treatment exists. Hepatocyte growth factor (HGF) has demonstrated antifibrotic and regenerative effects in preclinical and early-phase clinical studies and is a promising therapeutic candidate for vocal fold fibrosis. OBJECTIVE The aim of this study is to evaluate the efficacy and safety of KP-100LI, an intracordal formulation containing a recombinant human 5-amino-acid-deleted hepatocyte growth factor (dHGF) as the active pharmaceutical ingredient for improving voice function in patients with vocal fold scar and sulcus. METHODS This is a phase III, multicenter, randomized, placebo-controlled, double-blind, parallel-group confirmatory trial conducted at eight hospitals in Japan (protocol version 4.0, 21 July 2026). The study consists of a screening period, treatment period, and 24-week observation period in the double-blind phase, followed by a continuation phase in which eligible participants receive KP-100LI. A total of 62 participants aged 18–75 years with bilateral vocal fold scar and sulcus, and a Voice Handicap Index-10 (VHI-10) score of ≥11 at both screening assessments will be enrolled. Eligible participants will be randomly assigned to receive either KP-100LI or placebo. KP-100LI will be administered by bilateral intracordal injection at a total dose of 20 μg (10 μg per vocal fold) once weekly for four consecutive weeks. Participants will be followed for 24 weeks after completion of treatment in the double-blind phase. RESULTS The primary endpoint is the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score at Week 24 compared with baseline. Secondary endpoints include the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score at Weeks 4, 8, and 12; changes in VHI-10 scores, normalized mucosal wave amplitude (NMWA), and Grade, Roughness, Breathiness, Asthenia, and Strain (GRBAS) scale scores from baseline to Weeks 4, 8, 12, and 24 during the double-blind phase. In addition, during the continuation phase, the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score and changes in VHI-10 scores, NMWA, and GRBAS scores at Weeks 4, 8, 12, and 24 of the continuation observation period will be evaluated relative to baseline at Week 0 and baseline at Week 27. Safety assessments include adverse events and other clinical safety evaluations throughout the study. CONCLUSIONS This trial is designed to determine whether intracordal administration of KP-100LI improves voice-related outcomes in patients with vocal fold scar and sulcus. The results will provide important evidence regarding the efficacy and safety of dHGF-based regenerative therapy for these refractory vocal fold disorders. CLINICALTRIAL ClinicalTrials.gov NCT05627648; https://clinicaltrials.gov/study/NCT05627648?term=KP-100LI&rank=1 the Japan Registry of Clinical Trials jRCT2051220132; https://jrct.mhlw.go.jp/latest-detail/jRCT2051220132